Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed 
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
FTC Questions Apple News Over Alleged Bias Against Conservative Media 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
PARSIPPANY, N.J., Feb. 16, 2018 -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that the company is scheduled to present at the 2018 RBC Capital Markets Healthcare Conference at 9:30 AM ET on Wednesday, February 21, 2018 in New York City.
A live audio webcast of the Pacira presentation can be accessed by visiting the “Investors & Media” section of the company’s website at investor.pacira.com. A replay of the webcast will be archived on the Pacira website for two weeks following the presentation date.
About Pacira
Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) is a specialty pharmaceutical company dedicated to advancing and improving postsurgical outcomes for acute care practitioners and their patients. The company’s flagship product, EXPAREL® (bupivacaine liposome injectable suspension) was commercially launched in the United States in April 2012. EXPAREL utilizes DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. To learn more about Pacira, including the corporate mission to reduce overreliance on opioids, visit www.pacira.com.
Company Contact: Pacira Pharmaceuticals, Inc. Susan Mesco (973) 451-4030 [email protected]
